India: a threat to an industry or just misunderstood?
To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out.
Russia v Eurasia: national and regional differences in patentability
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain.
Considerations for biopharma under a first-inventor-to-file regime
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.
Biotech threats in the SPC system
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.
Post-grant patent challenges in Europe and the US: harmony at last?
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.
Generic battles: pay-for-delay in Brazil
While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case.
Who's first? New rules on filing patents
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.
Moving forward: biologics and biocomparables in Mexico
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.
Patent protection of traditional knowledge and biological material
Therapeutic substances used under the folk medicine practices of what is known as ‘traditional knowledge’ are protected by special provisions under Indian patent law. Archana Shanker and Vidisha Garg explore the pros and cons.
Slow but positive change? The evolution of section 3d
New definitions of efficacy are helping to clarify pharmaceutical patent challenges under the notorious Section 3d of the Indian Patents Act, says Rahul Vartak.